CSI Market
Sign In | Register

Caris Life Sciences Inc (CAI) Annual Cash Flow Statement

Annual · GAAP · USD millions
Access CAI quarterly Cash Flow →
Observing cash flow movements over recent quarters helps explain how Caris Life Sciences Inc adapts cash usage as operating conditions change.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Annual Report, GAAP in USD millions
ITEM 		(Dec 31 2025)
12 Months 		(Dec 31 2020) (Dec 31 2019) (Dec 31 2018) (Dec 31 2017)
Operating Activities
Income-68.09
Depreciation & amortization22.62
Amortization of Other Assets12.77
Increase (Decrease) in Deferred Revenue0.00
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability0.00
Provision For Loan Losses Expensed0.00
Increase (Decrease) in Materials and Supplies-20.75
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property0.00
Share-based Compensation70.01
Income (Loss) from Equity Method Investments0.00
Gains (Losses) on Extinguishment of Debt19.90
Gains Losses On Sales Of Assets5.59
Gain Loss On Disposition Of Property52.29
Provision Recovery Of Doubtful Accounts-
Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest-
Net Investment In Sales Type And Direct Financing Leases-
Income taxes0.00
Gain (Loss) on Disposition of Stock in Subsidiary0.00
Increase (Decrease) in Accounts Receivable-29.79
Increase (Decrease) in Accounts Payable11.04
Increase (Decrease) in Accrued Liabilities11.48
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets-5.15
Other Working Capital0.05
Other Noncash Income (Expense)1.22
Other net0.00
Payments for (Proceeds from) Other Operating Activities0.00
Discontinued operations0.00
Net Cash flow from Operating Activities83.16
Investing Activities
Capital Expenditures-16.26
Sale of Capital Items0.00
Short-term Investments Proceeds0.00
Short-term Investments Acq.0.00
Real Estate Investments0.00
Receipt Of Principal Payments On Direct Financing And Sales Type Leases-
Increase (Decrease) in Restricted Cash0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Payments to Acquire Businesses, Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Cash Divested from Deconsolidation0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities-16.26
Financing Activities
Short-term debt Net0.00
Other borrowing transactions-4.00
Long-term debt - borrowings27.87
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock528.27
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock10.27
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net102.69
Proceeds From Consolidated Vie-0.11
Proceeds From Long Term Credit Backed Line Of Credit Facility-
Principal Payments For Asset Long Term Debt-
Proceeds From Issuance Of Common And Preferred Stock-
Payments of Ordinary Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities664.99
Effect of exchange rate on cash flow0.13
Discontinued operations0.00
Free Cash Flow66.90
Total Cash Flow732.01
4 historic quarters locked

Sign in to unlock the full Caris Life Sciences Inc cash flow history.

Sign In Create Free Account

About Caris Life Sciences Inc Annual Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-K filings and normalized by CSIMarket.

Source & verification

  • Form: 10-K (Period: 20251231)
  • Filed with the SEC: March 3, 2026
  • Source: cai-20251231.htm

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0002019410-26-000016

Figures are derived from filed reports and may be restated. Historical data is subject to revision.

Untitled Document 





                    


    



  Get the full CSIMarket dataset:
  Subscribe
  API
  License